Lynch Syndrome (LS) is an inherited condition caused by pathogenic variants in DNA genes which result in an increased risk of colorectal, endometrial, and other cancers.

Lynch Syndrome (previously known as hereditary non-polyposis colorectal cancer (HNPCC) increases risk of developing bowel cancer to up to 80%

Approximately 200,000-300,000 people likely to have this inherited condition in the UK. However, it is estimated that only 5% of people with Lynch Syndrome have actually been diagnosed.

We are trying to change that!

Genetic testing can provide a definitive diagnosis for someone with Lynch and open up new screening and treatment options. All patients with colorectal (CRC) [DG27] and endometrial cancer [DG42] should now receive genetic testing according to NICE guidelines.

Come and learn how you can achieve that for your patients.

Our sessions are relevant to anyone who is part of a Cancer MDT.

To register your place via Eventbrite click here

Leading Lynch & Genomic experts will be leading the sessions including:

• Kevin Monahan, Consultant Gastroenterologist at St Mark’s Hospital and Co-Chair of the national NHS GMS Lynch Syndrome Oversight Group
• Adam Shaw, Consultant Geneticist at Guy’s and St Thomas’ and Co-Chair of the national NHS GMS Lynch Syndrome Oversight Group
• Nick West, Associate Professor of Pathology and Honorary Consultant in Gastrointestinal and Molecular Pathology, Leeds Teaching Hospitals NHS Trust
• Professor Emma Crosbie, Professor of Gynaecological oncology
• Laura Monje-Garcia, National lead nurse for the Lynch Syndrome project

If you can’t make this session, we have others available on the following dates:

• June 13th 1-2pm with colorectal focus
• September 22nd 1-2pm with colorectal focus